News | Nuclear Imaging | February 14, 2020

APAC Nuclear Imaging Market Projected to Grow at CAGR of 8.9%

GlobalData projects this growth to occur between 2019 and 2028 

Nuclear imaging equipment growth in 2020

February 14, 2020 — The nuclear imaging equipment market in the Asia-Pacific (APAC) region is expected to grow at a compound annual growth rate (CAGR) of 8.9 percent from US$0.7B in 2019 to US$1.5B by 2028, according to GlobalData, a leading data and analytics company.

China will be by far the fastest growing country in the region growing at a CAGR of 11.0 percent between 2019 and 2028, which is closely followed by the fastest growing markets: India, South Korea and Japan, respectively.

The company’s report, ‘Nuclear Imaging Equipment – Diagnostic Imaging Market Analysis and Forecast Model’ states that while inclination toward non-invasive disease diagnosis will be the main market driver, the increased aging population with cardiac and neurological ailments and growing cancer patients in both younger and older population will propel the market during the forecast period.

 

Sirivolu Manasa, medical devices analyst at GlobalData, commented: “GE Healthcare has remained as the market leader in APAC due to its innovation of advanced technologies by acknowledging the requirements of the patients. Regional companies like Canon Medical Systems Corp and Neusoft Medical Systems have also established themselves as competitors in this space apart from the other global manufacturers such as Siemens Healthineers AG and Philips Healthcare.”

 

In the APAC region, positron emission tomography/computed tomography (PET/CT) systems are the major revenue contributors within CT systems, with their market growing at a CAGR of 8.8 percent between 2019 and 2028, followed by single photon emission computed tomography/computed tomography (SPECT /CT) systems.

 

Manasa concluded: “The technological advancements in the medical field will have a positive impact on the growth of nuclear imaging equipment market. The demand for the products required specifically for each of the vital organs will help physicians make more accurate clinical decisions enhancing patient safety, driving the market forward.”

Related Content

Potassium Molybdate Mo 99 Source Vessels for RadioGenix System

Potassium Molybdate Mo 99 Source Vessels for RadioGenix System (Photo: Business Wire)

News | Radiopharmaceuticals and Tracers | February 18, 2020
February 18, 2020 — NorthStar Medical Radioisotopes, LLC, a
SIR-Spheres Y-90 resin

SIR-Spheres Y-90 resin microspheres are released into the hepatic artery.

News | Nuclear Imaging | February 14, 2020
February 14, 2020 —  ...
Varian announced it has received FDA 510(k) clearance for its Ethos therapy, an Adaptive Intelligence solution. Ethos therapy is an artificial intelligence (AI)-driven holistic solution that provides an opportunity to transform cancer care.
News | Image Guided Radiation Therapy (IGRT) | February 11, 2020
February 11, 2020 — Varian announced it has received FDA 510(k) c
The radiation therapy market is projected to grow in through 2026

Image courtesy of Accuray

News | Proton Therapy | February 10, 2020
February 10, 2020 — Amid technological advancement, and notable research and development activities, the global ...
Accuray TomoTherapy total body irradiation
News | Radiation Therapy | February 07, 2020
February 7, 2020 — Accuray Incorporated announced that two new studies demonstrate the benefits of the ...
Elekta Unity MR Linac system
News | Radiation Oncology | January 30, 2020
January 30, 2020 — Elekta announced that it signed a contract wit
ringing the cancer bell can do more harm than good, says an ASTRO study

Image courtesy of ASTRO

News | Radiation Oncology | January 27, 2020
January 27, 2020 — It's a scene that some cancer patients dream about: they celebrate the end of a course of radiatio
A 50-y-old postmenopausal woman with fibroadenoma (arrows) in left breast

A 50-y-old postmenopausal woman with fibroadenoma (arrows) in left breast. (A) Unenhanced fat-saturated T1-weighted MRI shows extreme amount of FGT (ACR d). (B) Moderate BPE is seen on dynamic contrast-enhanced MRI at 90 s. (C) Mean ADC of breast parenchyma of contralateral breast on diffusion-weighted imaging with ADC mapping is 1.5 × 10?3 mm2/s. (D) On 18F-FDG PET/CT, lesion is not 18F-FDG-avid, and BPU of normal breast parenchyma is relatively high, with SUVmax of 3.2. Photo courtesy of K Pinker, et al., Medical University of Vienna, Vienna, Austria

News | PET-MRI | January 27, 2020
January 27, 2020 — Researchers have identified several potentially useful...
Nuclear imaging of the spine shown on Philips Healthcare BrightView XCT

Image courtesy of Philips Healthcare

News | Nuclear Imaging | January 27, 2020
January 27, 2020 — According to the new market research report "...